|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administration_setting
|
outpatient
|
|
gptkbp:approves
|
gptkb:vaccine
|
|
gptkbp:availability
|
limited supply
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Sanofi
gptkb:Canada
gptkb:United_States
gptkb:Regeneron_Pharmaceuticals
Phase 3
reduced hospitalization rates
reduced viral load
improved symptoms
|
|
gptkbp:clinical_use
|
post-exposure prophylaxis
treatment of COVID-19
prevention of severe disease
|
|
gptkbp:collaborations
|
gptkb:Sanofi
|
|
gptkbp:community_health
|
improved patient outcomes
decreased transmission rates
reduced healthcare burden
|
|
gptkbp:composed_of
|
gptkb:casirivimab
gptkb:imdevimab
|
|
gptkbp:developed_by
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:emergency_services
|
gptkb:FDA
|
|
gptkbp:funding
|
government grants
private investments
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Regen-Cov
|
|
gptkbp:indication
|
mild to moderate COVID-19
|
|
gptkbp:invention
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:REGEN-COV
|
|
gptkbp:mechanism_of_action
|
neutralizing antibodies
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
WHO recommendations
CDC recommendations
|
|
gptkbp:regulatory_compliance
|
gptkb:Health_Canada
gptkb:European_Medicines_Agency
|
|
gptkbp:research_focus
|
combination therapies
COVID-19 variants
long-term efficacy
|
|
gptkbp:route_of_administration
|
subcutaneous injection
subcutaneous injection or intravenous infusion
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
single dose
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
allergic reactions
diarrhea
thrombosis
anaphylaxis
infusion reactions
|
|
gptkbp:storage
|
2 to 8 degrees Celsius
|
|
gptkbp:target_audience
|
high-risk patients
non-hospitalized patients
|
|
gptkbp:targets
|
gptkb:SARS-Co_V-2
|
|
gptkbp:bfsParent
|
gptkb:Regeneron_Pharmaceuticals
gptkb:Regeneron
|
|
gptkbp:bfsLayer
|
4
|